# Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases

Study · id `cardio:ct-nct04834089` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04834089](<https://clinicaltrials.gov/study/NCT04834089>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04834089

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 618 participants.

## Technical summary

Registry record NCT04834089. Randomized; double masking; primary purpose treatment. Start 2021-05 (anticipated); primary completion 2022-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 1/2
- Enrolled: 618 participants (planned count; ClinicalTrials.gov record NCT04834089, source copy `cardio:ctgov-nct04834089-2021-04-08`, retrieved 2026-10-26)
- Planned start: 2021-05 (anticipated) (ClinicalTrials.gov record NCT04834089, source copy `cardio:ctgov-nct04834089-2021-04-08`, retrieved 2026-10-26)
- Primary completion: 2022-05 (anticipated) (ClinicalTrials.gov record NCT04834089, source copy `cardio:ctgov-nct04834089-2021-04-08`, retrieved 2026-10-26)
- Completion: 2022-05 (anticipated) (ClinicalTrials.gov record NCT04834089, source copy `cardio:ctgov-nct04834089-2021-04-08`, retrieved 2026-10-26)
- Countries: Brazil (ClinicalTrials.gov record NCT04834089, source copy `cardio:ctgov-nct04834089-2021-04-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04834089-2021-04-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases
- Acronym: SOROCOV
- Condition: Immunosuppression
- Condition: Cancer
- Condition: COVID-19
- Condition: Other Complication of Kidney Transplant
- Condition: Chemotherapy
- Condition: Renal Disease
- Condition: Diabetes Mellitus
- Condition: Cardiovascular Diseases
- Condition: Chronic Obstructive Pulmonary Disease
- Intervention (Biological): AntiSARS-CoV-2 Serum
- Intervention (Other): Placebo
- Lead sponsor: Butantan Institute
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: a355ab42dc681c70f1c267b660917396859f7fe6b2d4f8a2fbffdee0f51b6f8a
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
